Teal Health Raises $22M for At-Home HPV Screening

Teal Health has successfully closed a $22 million Series A funding round, propelling its mission to broaden access to its FDA-authorized at-home HPV cervical cancer screening technology. The significant capital infusion, led by .406 Ventures, with continued support from Emerson Collective (managed by Yosemite), Forerunner, and Serena Ventures, alongside new investment from Japan's MPower Partners, brings the company's total funding to $45 million. This strategic financing arrives as the U.S. healthcare system grapples with significant gaps in preventive care, with nearly one-third of women not current on cervical cancer screenings due to access challenges.

The urgency for accessible screening solutions is underscored by upcoming federal mandates in January 2027, which will require most health plans to cover self-collection methods for cervical cancer screening. Teal Health, already a pioneer in this space with its speculum-free Teal Wand™, is strategically positioning itself to meet this anticipated surge in demand. The company's innovative approach bypasses the need for in-office visits and uncomfortable procedures, offering a private, convenient, and highly accurate alternative.

This latest funding will be instrumental in scaling Teal Health's partnership network, encompassing payors, health systems, employers, and healthcare providers. The goal is to integrate screening availability seamlessly into existing healthcare touchpoints and employee benefit programs. Furthermore, the company is enhancing its direct-to-consumer channels, aiming to transition at-home screening from an early-adopter option to a standard, widely embraced component of routine preventive care nationwide. Expansion of key clinical, commercial, technology, and operational teams is also a priority to support this growth.

Kara Egan, CEO and Co-Founder of Teal Health, emphasized the company's patient-centric design: "We designed Teal for all women, whether they are behind on their screening or coming due. Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen." She added, "This funding allows us to scale to meet the demand of patients and providers. It’s clear this option is preferred by women and now we can ensure everyone has a way to stay healthy."

The effectiveness and patient satisfaction with Teal Health's model are compelling. Data indicates that 59% of women utilizing Teal are previously underscreened, highlighting the platform's success in reaching underserved populations. The end-to-end experience, which includes telehealth consultations, at-home sample collection, secure results delivery, and facilitated follow-up care, has garnered an average user rating of 4.95 out of 5. This high satisfaction rate validates the market's appetite for such convenient and effective health solutions.

Kathryn Taylor Reddy, Partner at .406 Ventures, commented on the investment's strategic timing: "Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy. With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare." The cervical cancer market, which sees thousands of U.S. women diagnosed annually, presents a critical opportunity for preventative solutions like Teal Health's, especially given that it is one of the most preventable forms of cancer.

Since its FDA authorization in 2025, Teal Health has not only screened thousands of women but has also contributed to national screening guidelines and advanced research through 17 peer-reviewed publications. By forging partnerships with healthcare entities and offering direct purchase options, the company is actively working to close screening gaps and alleviate pressure on clinical resources, ensuring more women can access vital preventive care.